A pharmaceutical company that uses a zebrafish drug-screening platform to find drug candidate molecules that have the capacity to promote regeneration of tissues. Their drug candidate MSI-1436 is being developed and tested for the treatment of heart disease, Duchenne Muscular Dystrophy and diabetic nephropathy.
Voot Yin, Novo Bioscience’s chief scientific officer was awarded a two-year $1.5 million Small Business Innovation Research grant in 2017 from the National Heart, Lung and Blood Institute, an institute of the National Institutes of HealthHealth (NIH), to study trodusquemine in the pig. The pig heart closely resembles that of a human. The drug is being tested as a treatment for acute heart attack and also for chronic heart injury, Duchenne muscular dystrophy, skeletal muscle injury and spinal cord damage.
Novo Biosciences was founded by Kevin Strange and Voot P. Yin. Strange was president of Mount Desert Island (MDI) Biological Lab from 2009 to 2016 and and Yin was an MDI Biological Laboratory faculty member. Together along with Michael ZasloffMichael Zasloff of Georgetown University, they are co-inventors of the drug candidate MSI-1436, also called trodusquemine. Strange stepped down as president of MDI Bio Lab to pursue development of MSI-1436 as CEO of Novo Biosciences.
Voot Yin, Novo Bioscience’s chief scientific officer was awarded a two-year $1.5 million Small Business Innovation Research grant in 2017 from the National Heart, LungLung and Blood Institute, an institute of the National Institutes of Health (NIH), to study trodusquemine in the pig. The pig heart closely resembles that of a human. The drug is being tested as a treatment for acute heart attack and also for chronic heart injury, Duchenne muscular dystrophy, skeletal muscle injury and spinal cord damage.